The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Abbott; Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Merck
Consulting or Advisory Role - Tempus
Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors.
 
Karen A. Autio
Research Funding - ARMO BioSciences (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Merck (Inst); Pfizer (Inst)
 
Hendrik-Tobias Arkenau
No Relationships to Disclose
 
Bert H. O'Neil
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; Halozyme
Speakers' Bureau - Celgene
Travel, Accommodations, Expenses - Bayer; Merck KGaA
 
Johanna C. Bendell
Research Funding - Abbott/AbbVie (Inst); Agios (Inst); Apexigen (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Incyte (Inst); Ipsen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Nektar (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pieris Pharmaceuticals (Inst); Sanofi (Inst); Stem CentRx (Inst); SynDevRx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TG Therapeutics (Inst); Tyrogenex (Inst)
 
Anthony El-Khoueiry
Honoraria - Bayer; Bristol-Myers Squibb; Merrimack; Novartis
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Eisai; EMD Serono; Roche
Research Funding - Astex Pharmaceuticals; AstraZeneca
 
James Strauss
No Relationships to Disclose
 
Amy Weise
No Relationships to Disclose
 
Nataliya Volodymyrivna Uboha
Consulting or Advisory Role - EMD Serono; Flatiron Health; Gerson Lehrman Group
 
Naiyer A. Rizvi
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences; Gritstone Bio
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Regeneron
 
Beiyao Zheng
Employment - CytomX Therapeutics
 
Luc Desnoyers
Employment - CytomX Therapeutics
 
Mark Stroh
Employment - CytomX Therapeutics
 
Lori Carman
Employment - CytomX Therapeutics
 
Rachel W. Humphrey
Employment - CytomX Therapeutics
 
Matthias Will
Employment - CytomX Therapeutics
 
Valentina Boni
No Relationships to Disclose
 
Alexander I. Spira
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); CytomX Therapeutics (Inst); Ignyta (Inst); Incyte (Inst); LAM Therapeutics (Inst); Macrogenics (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novartis (Inst); Roche (Inst); Takeda (Inst); Trovagene (Inst)
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; MedImmune; Merck; NCI; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences